Q-omics provides the consensus-scored CLN3 profile across patient tissues and cancer cell-line models. CLN3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CLN3 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, CLN3 RNA expression shows 17,615 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where CLN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLN3 survival associations across molecular data types. CLN3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLN3 RNA expression–survival associations across cancer types. High CLN3 expression shows unfavorable associations in UVM, LIHC, LGG and UCS, but favorable associations in ACC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CLN3 RNA expression.
This table summarizes CLN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CLN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLN3 shows lower tumor expression in THCA and higher tumor expression in BLCA, LIHC, HNSC, KIRP and STAD. The BLCA box plot shows higher CLN3 RNA expression in tumor versus normal tissue (log2 FC = +0.816, t-test p < 0.001).
This table shows molecular features associated with CLN3 in patient tissues and cancer cell lines. In patient samples, CLN3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BREAST.
